Core Viewpoint - BGM Group Ltd is undergoing a significant leadership transition aimed at enhancing its technological transformation and sustainable growth, with a focus on innovation and strategic upgrades in response to market opportunities and challenges [1][5]. Leadership Changes - Mr. Zhanchang Xin has resigned as Chairman, effective March 1, 2025, and will be succeeded by Mr. Chen Xin, the current CEO [2][3]. - Mr. Chen Xin has extensive experience in market consolidation and corporate management, having led the acquisition of Duxiaobao Intelligent Technology and previously worked in autonomous driving algorithm development [3][4]. - Mr. Lin Zhang has been appointed as an independent director and will chair the compensation committee, bringing rich experience in AI model architecture and deep learning projects [4][5]. Strategic Focus - The company is strategically focused on technology fields including AI applications, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [6]. - BGM Group utilizes big data mining and AI Agent technology to provide comprehensive AI solutions and intelligent robot services, particularly in the insurance sector [7]. - In biopharmaceuticals, the company produces key products like oxytetracycline API and crude heparin sodium, integrating AI-assisted decision-making to optimize production and supply chain processes [8].